Observational TFESI Efficacy in Lumbar Radicular Pain
NIH registered an observational study (NCT07538765) evaluating the effectiveness of transforaminal epidural steroid injections (TFESI) in patients aged 18 to 90 with radicular low back pain caused by lumbar disc herniation who did not improve with conservative treatment. The three-month study tracks pain reduction using the Visual Analog Scale and functional improvement using the Oswestry Disability Index. No compliance obligations or deadlines are created by this registry entry.
AI-Guided Atrial Fibrillation Detection After Ischemic Stroke: Prospective Randomized Trial
NIH registered a prospective randomized trial (NCT07540065) comparing AI-guided atrial fibrillation risk stratification plus intensified rhythm monitoring (wearable devices, extended ECG patches) against standard care in post-ischemic stroke patients. The trial enrolls an Active Follow-up Group and a Standard Follow-up Group, with conditions including Atrial Fibrillation, Stroke, and Artificial Intelligence. The primary hypothesis is that AI-assisted ECG analysis will significantly increase AF detection rates and enable earlier anticoagulation decisions while reducing unnecessary bleeding risk exposure.
VALsartan on atRIAl Mitral Regurgitation Pilot Randomized Controlled Trial Phase 2
NIH ClinicalTrials.gov registered a Phase 2 pilot randomized controlled trial (NCT07539298) evaluating valsartan versus placebo for treatment of atrial functional mitral regurgitation in adults with preserved left ventricular ejection fraction. The 12-month study will assess progression reduction, mitral valve leaflet remodeling, and safety/tolerability. Participants will undergo 3D echocardiography, 6-minute walk tests, and Kansas City Cardiomyopathy Questionnaire assessments.
BPS-Tech Pilot Trial for Eighth Graders
NIH has registered a pilot clinical trial (NCT07540819) testing a single-session writing exercise called Best Possible Self-Tech (BPS-Tech) with eighth graders. The study aims to assess feasibility and acceptability of classroom delivery, and to examine associations between textual features and positive affect outcomes.
Phase I CY-219 CAR-T Cell Injection for Relapsed/Refractory B-Cell Lymphoma
The National Institutes of Health registered a Phase I clinical study (NCT07539688) evaluating the safety and efficacy of CY-219 CAR-T cell injection in patients with relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma and transformed indolent B-cell lymphoma. The open-label, single-arm trial is sponsored by Changebridge Pharmaceutical Co., Ltd. and enrolls patients meeting specific disease criteria.
Phase 2 Emapalumab Trial for Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction
The NIH has registered a Phase 2 clinical trial on ClinicalTrials.gov testing emapalumab versus placebo in lung transplant recipients experiencing acute lung allograft dysfunction (ALAD), a serious complication with no approved treatment. The trial (NCT07538336) plans to enroll approximately 90 participants with a primary completion date of April 20, 2026. This is a routine trial registration providing public access to study parameters and eligibility criteria.
Optimizing Early Nutrition Management of Extremely and/or Very Preterm Infants
NIH ClinicalTrials.gov has registered a clinical quality improvement study (NCT07538999) evaluating an early nutrition management bundle for extremely and/or very preterm infants. The bundle combines three interventions: individualized human milk feeding, early enteral zinc supplementation, and routine parenteral carnitine supplementation. The study will assess clinical outcomes including growth, organ function, and neurodevelopment compared to routine nutritional strategies.
QI-019B Phase 1 Trial for Relapsed/Refractory Multiple Myeloma
NIH registered Phase 1 trial NCT07539233 evaluating QI-019B Injection in patients with relapsed/refractory multiple myeloma. The single-arm, open-label, single-center study will assess safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the investigational drug.
Virtual Intervention for Behavioral Health in Emerging Adults; VIBE in the Parks
NIH ClinicalTrials.gov has registered a randomized clinical trial (NCT07539636) evaluating a digital behavioral health intervention, 'VIBE in the Parks', for adolescents and young adults experiencing anxiety and depression. The study will be conducted at four Chicago Park District sites, comparing the digital treatment to a control condition using a digital workbook.
NY OMH Opens 24/7 Crisis Stabilization Center in Brooklyn
NY OMH announced the opening of a new 24/7 Supportive Crisis Stabilization Center operated by Services for the UnderServed at 2862 Fulton St. in East New York, Brooklyn. The facility, licensed in partnership with OASAS, provides voluntary, short-term behavioral health stabilization services for up to 24 hours as an alternative to unnecessary emergency room visits. The center received $1.2 million in start-up funding and $4.5 million in operating funding over five years.
34-Unit Schenectady Specialized Mental Health Housing Groundbreaking
Governor Hochul announced the groundbreaking for Mohawk Heights, a 34-unit specialized housing development in Schenectady for adults living with mental illness who are homeless or at risk. The project is funded by $15.6 million from the Office of Mental Health plus approximately $750,000 in annual operating funds, with construction financing from DASNY. The 11,459-square-foot building is expected to open in Q1 2027.
New Crisis Stabilization Center Opens in Utica
The New York State Office of Mental Health announced the opening of a new Supportive Crisis Stabilization Center in Utica, operated by Upstate Caring Partners. The facility, located at 1002 Oswego Street, provides 24/7 behavioral health crisis services including immediate stabilization and therapeutic support for individuals experiencing mental health or substance use challenges. The center was awarded $3.8 million over five years and is licensed in partnership with the Office of Addiction Services and Supports.
Program Memos
The CA Department of Aging Licensing publishes a landing page providing access to program memos and policy updates for aging services programs in California. No specific regulatory content, memos, or policy changes are provided in this listing — the page serves as a navigation portal with a subscription link for receiving future communications.
Bridge to Recovery $55.84M Grant Round 2 Closed
The California Department of Aging (CDA) announces that Round 2 of the Bridge to Recovery grant program is now closed. The $55.84 million program supports in-center congregate services for at-risk older adults and people with disabilities, providing funding to day-service providers for infection prevention and workforce shortage mitigation.
Regulatory Updates and Policy Documents Portal
The California Department of Aging provides public access to its regulatory actions including proposed and approved regulations under the Older Americans Act and California Welfare and Institutions Code. Current proposals include three regular rulemaking items covering quarterly reviews, definition of local government units, and revocation of Area Agency on Aging designations. The page outlines the public comment process and hearing procedures in compliance with California Government Code section 11346.5.
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
NIH ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07538180) evaluating a three-stage treatment protocol for newly diagnosed elderly patients with MYC/BCL2 double-expressor DLBCL. The protocol consists of chemotherapy-free SCR therapy (Serplulimab, Chidamide, Rituximab), followed by R-CHOP chemotherapy, then maintenance therapy. The trial enrolls elderly patients and allows R-miniCHOP for frail patients over 75 years.
MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES)
NIH registered a Phase 2 clinical trial (NCT07538284) titled MIDDIES on ClinicalTrials.gov. The trial will study whether nighttime self-administration of nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients undergoing major abdominal surgery, compared with placebo.
QIPB in Hip Surgery - Opioid Consumption Measurement Study
This single-center retrospective study registered on ClinicalTrials.gov examines patients who underwent hip surgery between May 2025 and November 2025. The study compares patients receiving Quadro Iliac Plane Block (QIPB) plus patient-controlled analgesia against a control group using only patient-controlled analgesia. Primary endpoint is total opioid consumption over 24 hours, with secondary endpoints including pain scores and rescue analgesia requirements.
Observational Case Series of Futsal Goalkeeper Barrier-Step Movement
NIH ClinicalTrials.gov registered observational study NCT07539246 examining barrier-step movement in three elite male futsal goalkeepers. The study used high-speed video analysis to characterize movement phases and body angles during standardized low ball stimulus responses. No compliance obligations or regulatory requirements are created by this registration.
Phase 2 Dapagliflozin Spironolactone Aortic Valve Replacement Trial
NIH registered a Phase 2 randomized controlled trial (NCT07539259) evaluating dapagliflozin and spironolactone in patients with severe aortic stenosis undergoing aortic valve replacement. The four-arm trial will assess whether these heart failure medications improve left ventricular mass regression, myocardial health, and patient-reported outcomes compared to standard-of-care alone over 12 months.
Suzetrigine Phase 3 Trial for Cardiac and Bariatric Surgery Patients NCT07539623
NIH registered Phase 3 clinical trial NCT07539623 on ClinicalTrials.gov, evaluating Suzetrigine as an addition to multimodal pain regimens for post-operative pain management in bariatric and cardiac surgery patients. The prospective, randomized study will assess whether Suzetrigine reduces opioid consumption and pain scores compared to placebo in participants undergoing weight-loss surgery or sternotomy.
Study Compares Caries Removal Methods, Oral Microbiome Effects
The National Institutes of Health registered a clinical study on ClinicalTrials.gov (NCT07538089) evaluating how selective and non-selective caries removal methods affect oral microbiome composition using 16S rRNA gene sequencing. The study targets dental caries patients and will assess microbial diversity outcomes from two intervention approaches.
Oral Probiotics vs Placebo Pakistani Moderate Acne Study
ClinicalTrials.gov registered a randomized controlled trial (NCT07539129) evaluating oral probiotics versus placebo in 64 Pakistani patients with moderate Acne Vulgaris over 12 weeks. The primary endpoint is reduction in total acne lesion count; secondary endpoint is change in serum Interleukin-6 levels. The study will use GAGS scoring and standardized photography for clinical assessment.
Phase 3 RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
NIH registered a Phase 3 randomized controlled clinical trial (NCT07540390) evaluating GAPP induction therapy combined with concurrent chemoradiotherapy and toripalimab maintenance for high-risk locoregionally advanced nasopharyngeal carcinoma (Stage III, AJCC 9th edition). The experimental arm combines PD-1 antibody (toripalimab), anlotinib, cisplatin, gemcitabine, and radiation, while the control arm uses the current guideline-recommended GPP induction chemotherapy regimen. The multicenter open-label study aims to generate evidence-based data on the efficacy and safety of this novel combination.
Proposed National Qualification Standard for Pharmacist Prescribing
The Pharmacy Board of Australia has opened public consultation on a proposed national qualification standard for pharmacist prescribing, seeking feedback until 15 June 2026. The draft Endorsement for scheduled medicines and accompanying guidelines would establish consistent education and training requirements across all Australian states and territories. Over 40,000 registered pharmacists would be affected by the new standard, which covers physical examination, diagnostics, clinical decision-making, and referral practices.
Joint Warning on Predatory Superannuation Release for Dental Treatments
The ATO and Ahpra issued a joint warning on 14 April 2026 about predatory practices by health practitioners and third parties who exploit Australians into inappropriately accessing superannuation early for dental or cosmetic treatments. The agencies outlined red flags including social media advertising of early super access, requests for myGov credentials, and practitioners recommending unnecessary expensive treatments. Between 2019 and 2025, Ahpra received 95 complaints about practitioners involved in compassionate release of superannuation, resulting in two doctors referred to tribunals for allegedly false documentation, one doctor cautioned, and one dentist with conditions imposed on registration.
AHPRA Board Vacancies — Applications Open, Close 10 May 2026
AHPRA has opened applications for appointment to its Board. The agency seeks community members with expertise in health, education, business administration, or regulation, and particularly encourages Aboriginal and/or Torres Strait Islander Peoples to apply. Applications close on Sunday 10 May 2026 at 11:55pm Australian Eastern Standard Time.
Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression Phase 2 Randomized Controlled Trial
The NIH National Library of Medicine has registered a Phase 2 multicenter randomized controlled trial (NCT07539805) evaluating sertraline combined with Lactobacillus crispatus versus sertraline combined with placebo in adolescents aged 12-18 with major depressive disorder. The 8-week trial includes clinical assessments and safety monitoring every 4 weeks. No compliance obligations or deadlines are imposed on external parties.
Social Media Support Groups for Adolescent Vaping Cessation - Pilot
NIH has registered a pilot study (NCT07540780) on ClinicalTrials.gov evaluating the Quit the Hit Toolkit, a social media-based nicotine vaping cessation program adapted for teens and young adults in community settings. The study will assess feasibility and acceptability of the intervention targeting vaping, vaping cessation, and nicotine dependence. No compliance obligations or regulatory deadlines are created by this study registration.
Optimizing Weblink Design in Digital Vaccination Invitations to Raise Trust and Booking Intention: Online Experiment 3
NIH registered a behavioral research study (NCT07538349) examining how weblink design in digital vaccination invitation emails affects recipient trust and appointment booking intention. The study plans to enroll 4,000 participants (2,000 from the UK and 2,000 from the US) testing three link formats: an NHS control link and two experimental weblink variants including an improved version and a text-embedded hyperlink. This is a clinical trial registration entry documenting study design rather than a regulatory action or compliance requirement.
Observational Study on ADEM Outcome Predictors in Children
The National Institutes of Health has registered an observational study (NCT07540182) aimed at determining outcome predictors in children diagnosed with acute disseminated encephalomyelitis (ADEM). The study will observe patients with ADEM, encephalomyelitis, and encephalopathy conditions. No new compliance obligations or regulatory requirements are established by this study registration.
oXiris Hemofilter in Septic Shock With AKI Trial
NIH registered a multicenter retrospective observational study (NCT07539883) evaluating the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury requiring continuous renal replacement therapy. The study uses a Target Trial Emulation approach to compare patients treated with oXiris® filters against standard CRRT filters, examining in-hospital mortality, fluid balance, and vasopressor requirements. The study addresses inconsistent evidence regarding whether oXiris® improves survival through endotoxin and cytokine removal.
CHW Diabetes Program for Rural, Low-Income Patients
NIH has registered a clinical trial (NCT07538505) evaluating a Community Health Worker (CHW) program for patients with type 2 diabetes in rural and low-income settings. The study will assess whether monthly diabetes education classes and weekly mobile health check-ins improve blood sugar control, program sustainability, and feasibility. Participants will be recruited from rural clinics remote from the research team.
WISE Trial: Therapist-Supervised Wrist Exercise vs Usual Care for Fracture Recovery
NIH registered Clinical Trial NCT07538323, the WISE (Wrist Injury Strengthening Exercise) study, a randomized controlled trial comparing therapist-supervised exercise therapy against usual care self-management advice for adults aged 50 and older recovering from wrist fractures. The trial will measure pain and functional improvement using the Patient Rated Wrist Evaluation questionnaire at 6 months post-injury. Participants receive either supervised therapy sessions (one 60-minute session plus two 30-minute sessions) plus usual-care advice, or usual-care advice alone.
Adductor Canal Block With Tourniquet for Posterior Knee Pain After Total Knee Arthroplasty
NIH registered clinical trial NCT07539467, a randomized study comparing Tourniquet-Assisted Adductor Canal Block (T-ACB) versus Standard Adductor Canal Block (S-ACB) for managing posterior knee pain after total knee arthroplasty. The trial enrolled patients with gonarthrosis and tested whether applying a thigh tourniquet postoperatively alongside the adductor canal block improves pain control at the back of the knee. Results from this Phase 4 trial may inform regional anesthesia protocols for knee replacement recovery.
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
NIH's ClinicalTrials.gov has registered NCT07538882, a prospective observational study evaluating an AI model's ability to assist clinical physicians in staging hepatocellular carcinoma (HCC) and making treatment decisions. The Multi-Rater Multi-Case crossover study will compare physician accuracy under unassisted versus AI-assisted conditions across different hospital tiers to determine whether AI can reduce diagnostic and therapeutic heterogeneity in HCC care.
MG-K10 Phase III Trial, Adolescents, Moderate-to-Severe Atopic Dermatitis
NIH registered a Phase III clinical trial (NCT07540442) for MG-K10, a humanized monoclonal antibody injection, in adolescents with moderate-to-severe atopic dermatitis. The randomized, double-blind, placebo-controlled, parallel-group study aims to confirm the efficacy and safety of MG-K10 monotherapy. Trial conditions are limited to atopic dermatitis; no other indications are listed.
Virginia Board of Dentistry Adds Dental Hygienist Monetary Penalty Case
Mistie Dodson, a dental hygienist licensed in Stephens City, VA, received a Monetary Penalty and Terms Imposed-Other from the Virginia Board of Dentistry on April 15, 2026. The enforcement action is recorded under License Number 0402203415. No specific violation details or penalty amount are stated in the source.
Web-Based Stroke Diagnostic Tests Validation Study (Observational, NCT07538076)
The NIH registered observational study NCT07538076 to validate two web-based diagnostic tests — the Star Cancellation Test and Line Bisection Test — for assessing visuospatial neglect in hemiplegic stroke patients. The study will compare digital tablet-and-stylus versions of these tests against conventional paper-and-pencil assessments to evaluate diagnostic accuracy and clinical usability. Participants include stroke patients who will complete both conventional and digital versions of each test along with routine cognitive assessments.
Pilot Study: Mental Health Treatment Toolkit for Autistic Individuals
The Organization for Autism Research (OAR) registered a pilot study (NCT07539519) to improve mental health treatment for autistic individuals. The study will conduct remote focus groups to identify barriers and develop a prototype therapist resource, which will then be pilot tested in a community clinic setting. Participants will receive either enhanced psychotherapy or treatment as usual.
ADEPT Diarrhea Prediction Tool Pilot, LMICs
NIH has registered a pilot before-after feasibility trial testing the Accessible Diarrhea Etiology Prediction Tool (ADEPT), a mobile phone-based clinical decision-support application, among informally trained healthcare providers in low- and middle-income countries. The study aims to assess the tool's acceptability, feasibility, and utility in reducing inappropriate antibiotic prescribing for pediatric diarrhea. Participants will use the ADEPT application during routine patient care, with outcomes measured before and after implementation.
Sup19 CAR-T Phase 1 Trial for CD19 Therapy Failures and B-Acute Lymphoblastic Leukemia
NIH registered a Phase 1 clinical trial (NCT07539610) evaluating Sup19 CAR-T cells in patients with B-Acute Lymphoblastic Leukemia or B-ALL/Lymphoma where prior CD19-targeted therapy has failed or CD19 is weakly expressed. The single-arm prospective study will assess safety and efficacy of the investigational cell therapy product.
Multi-Omics Analysis of Lens Zonule Relaxation in PACG Pathogenesis
NIH registered observational clinical study NCT07539675 on ClinicalTrials.gov examining differential molecular expression in Primary Angle-Closure Glaucoma patients with zonular laxity compared to those without and controls. The study involves no experimental interventions and seeks to construct a mechanistic network from identified molecules.
Phase 2 Trial of Absorbable and Moldable Skull Base Support Plates in Endoscopic Endonasal Surgery
NIH registered a Phase 2 clinical trial (NCT07539792) on April 20, 2026, to evaluate the efficacy and safety of absorbable and moldable skull base support plates used in extended endoscopic endonasal transsphenoidal surgery for sellar tumors. The primary endpoint is the incidence of cerebrospinal fluid (CSF) rhinorrhea within 1 month after surgery; secondary endpoints include intracranial infection rates, surgery duration, hospital stay length, and nasal complications. The study is a prospective, randomized, controlled trial.
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
NIH registered a Phase 2 clinical trial (NCT07540832) evaluating WGI-0301 in combination with Lenvatinib in patients with advanced hepatocellular carcinoma (HCC) at multiple hospital sites. The open-label study will assess safety, tolerability, pharmacokinetics, and early efficacy signals of the combination therapy.
TUVA BX and iCover Stent Grafts BEVAR Observational Study
ClinicalTrials.gov registered an observational study collecting retrospective patient data on TUVA BX and iCover stent grafts used during branched endovascular aortic repair (BEVAR) to treat complex aortic aneurysms. The multi-center, single-arm study will review medical records from the original procedure through the 1-year follow-up visit for patients with thoracoabdominal aortic aneurysms or abdominal aortic aneurysms. No patient groups are assigned to specific interventions.
Maryland Home Visiting Week Proclaimed April 20-24, 2026
Governor Wes Moore of Maryland has proclaimed April 20-24, 2026 as Maryland Home Visiting Week. The proclamation recognizes early childhood home visiting programs and parenting education as tools to promote healthy child development, strengthen families, and reduce the risk of abuse and neglect. The observance is symbolic and does not create enforceable obligations or penalties.
FY 2025-26 Q2 Quarterly Performance Report Now Available
The Florida Department of Health's Division of Medical Quality Assurance released the FY 2025-26 Quarterly Performance Report for Quarter Two, covering key trends in licensing, enforcement, and financial information. The report is required under sections 456.005 and 456.025(9), Florida Statutes, and provides quarterly snapshots for MQA staff, board members, consumers, and other stakeholders.
Council on Dental Hygiene Meeting Documents - April 2026
The Florida Board of Dental Hygiene posted meeting documents for the Council on Dental Hygiene scheduled April 21, 2026. The posting includes the meeting agenda and public book. A FAR Notice document is also available. All materials are open to public inspection per Florida Statute 456.014.
California Respiratory Therapy Laws and Regulatory Codes Index
The California Respiratory Care Board publishes an index of state laws and regulations governing respiratory therapy practice. The index covers the Business and Professions Code provisions for respiratory therapy including certification, education standards, suspension/revocation, and enforcement, as well as the California Code of Regulations Title 16 covering applications, continuing education, scope of practice, citations, and fees. The board currently reports no pending regulations and maintains a rulemaking calendar.
Complaint Review Process for Respiratory Care Practitioners
The California Respiratory Care Board publishes its complaint review process for respiratory care practitioners (RCPs). The document informs consumers, employers, and licensees how to file complaints against RCPs for violations including sexual misconduct, substance abuse, incompetent practice, falsifying patient records, and unlicensed practice. The RCB states it will pursue immediate suspension when a licensee poses an immediate threat to public safety.
Navigation Portal for Respiratory Care Discipline
The California Respiratory Care Board provides a navigation portal for disciplinary information, linking to final disciplinary actions, license search tools, document request services, automated status updates, and enforcement-related policies.
Guidelines for Licensed Midwives Using Birth Assistants
The Washington State Department of Health Midwifery Program issued updated guidelines clarifying appropriate duties for licensed midwives versus unlicensed birth assistants. The guideline distinguishes clinical tasks requiring licensed midwife judgment (prenatal/intrapartum/postpartum exams, vital sign assessment, fetal heart tone assessment, APGAR scoring, newborn transition assessment) from duties appropriate for birth assistants under direct supervision (labor support, supply checks, vital sign reporting, newborn monitoring, breastfeeding assistance, documentation). The document explicitly states it is not legally binding and does not constitute a duly promulgated regulation.
Midwifery Complaint Process Guide, Washington State
The Washington State Department of Health issued a guide explaining the complaint and disciplinary process for licensed midwives under RCW 18.130 (Uniform Disciplinary Act). The guide covers report intake, case assessment, investigation procedures, timelines, enforcement actors, and due process requirements. It applies to all licensed midwives in Washington State.
Adiponectin Biomarker Trial for Metabolic Disorders
NIH registered an open-label randomized controlled trial (NCT07539584) evaluating whether high-molecular-weight adiponectin levels predict treatment response in 130 adults aged 40-65 with type 2 diabetes and metabolic dysfunction-associated fatty liver disease. Patients are randomized to SGLT2 inhibitor monotherapy, GLP-1 receptor agonist monotherapy, combination therapy, or no drug therapy. The primary outcome is change in serum HMW-adiponectin levels over 6 months; secondary outcome is change in liver steatosis measured by Controlled Attenuation Parameter.
MOCHA Perinatal Mental Health Integration Study Registration
NIH registered observational study NCT07540585 examining a Collaborative Mental Health Care Program integrated into high-risk obstetric inpatient settings. The single-arm implementation study will assess feasibility, acceptability, and fidelity of delivering brief inpatient psychotherapy, symptom monitoring, and three-month post-discharge follow-up for pregnant and postpartum patients with depression, anxiety, ADHD, and PTSD symptoms.
Effects of Menstrual Cycle on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Gynecologic Surgery
The National Institutes of Health registered observational study NCT07539831 on April 20, 2026. The study evaluates the effect of menstrual cycle phase (follicular vs. luteal) on optic nerve sheath diameter measurements in women undergoing elective laparoscopic gynecologic surgery. Researchers will assess perioperative ONSD measurements and postoperative outcomes including nausea, vomiting, and cognitive function.
Real-World Cohort Study Comparing Adjuvant HP vs T-DM1 in HER2+ Breast Cancer Non-pCR Patients
NIH's ClinicalTrials.gov registered a multicenter, retrospective, real-world cohort study (NCT07540520) comparing two adjuvant treatment regimens for HER2-positive breast cancer patients with non-pCR after neoadjuvant therapy: trastuzumab combined with pertuzumab (HP group) versus ado-trastuzumab emtansine (T-DM1 group). The study will analyze data from patients treated between July 2019 and July 2025 with a planned enrollment of 2,000 cases.
Effects of Low-Intensity Blood Flow Restriction Training on Strength and Kicking Performance in Taekwondo Athletes
NIH registered a new clinical trial (NCT07538037) on ClinicalTrials.gov investigating the effects of low-intensity blood flow restriction training (LI-BFRT) on lower-limb strength and kicking performance in taekwondo athletes. The study examines physical performance and athletic performance conditions using LI-BFRT and HIRT interventions. This is an informational study registration; it creates no compliance obligations for external parties.
Phase 1 PK Study of HRS9531 Injection in Mild to Normal Hepatic Function
The NIH ClinicalTrials.gov registry has published a Phase 1 clinical study (NCT07540754) to evaluate the pharmacokinetics of HRS9531 Injection in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function. The study will also assess safety. Participants have conditions of Diabetes Mellitus and Weight Loss. The study was registered with an anticipated date of April 20, 2026.
Phase 1 Mirdametinib Trial for CNS Tumors
NIH registered Phase 1 trial NCT07539441 to evaluate mirdametinib as a treatment for central nervous system tumors, specifically glioma and neurohistiocytosis. The study is listed on ClinicalTrials.gov as a Phase 1 safety and efficacy assessment. No compliance obligations or deadlines are associated with this registration notice.
Benmelstobart, Anlotinib, and Chemotherapy for Extensive-stage Small Cell Lung Cancer
NIH ClinicalTrials.gov registered a Phase 2 single-center study at Shanghai Pulmonary Hospital evaluating benmelstobart plus anlotinib and platinum-etoposide chemotherapy with sequential thoracic radiotherapy in 33 adult patients with previously untreated extensive-stage small cell lung cancer. The open-label, non-randomized trial uses objective response rate as the primary endpoint.
Safety Evaluation of Bioactive Glass Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors
The NIH ClinicalTrials.gov registry has recorded a Phase safety trial (NCT07540468) evaluating the use of bioactive glass-containing bone cement combined with intraoperative ultrasound for patients with metastatic bone tumors. The study aims to assess safety and feasibility of this combined treatment approach for bone stabilization and pain reduction. All participants will receive standard care plus the study intervention with close safety monitoring.
Effect of AI Critical Appraisal Training on Critical Thinking in Nursing Students
NIH registered a new cluster randomized controlled trial (NCT07538986) evaluating an AI Critical Appraisal Training method against traditional case-based learning for undergraduate nursing students. The study measures critical thinking disposition, AI literacy, and clinical reasoning skills pre- and post-intervention, with no stated compliance obligations for external parties.
Connected Toothbrush Study for Children Post-Operating Room Treatment
NIH ClinicalTrials.gov has registered an observational study (NCT07539064) titled 'Children in the Operating Room: Kids That go Thru Operating Room Will be Given a Connected Health Toothbrush, Kids Anticavity Toothpaste and Behavioral Health Intervention to Reduce Claim Costs.' The study examines whether compliance and brushing adherence using a connected toothbrush with a behavioral health intervention can improve oral health outcomes for children previously treated for caries in an operating room setting.
AL001 vs Lithium Carbonate Phase 1 Bipolar I Disorder Trial
NIH registered Phase 1 trial NCT07540338 to assess safety and brain/plasma pharmacokinetics of investigational drug AL001 (a crystallized lithium formulation) compared to marketed immediate-release lithium carbonate in subjects with Bipolar I Disorder. The crossover study will enroll participants who take each drug for 14-day periods at MGH research unit with MRI and blood draw monitoring. No compliance obligations are imposed by this registry entry.
CMS Has Limited Oversight of Selected Compounded Drugs in Medicare Part D
HHS OIG completed an audit (A-05-21-00008) of CMS oversight of compounded drugs under Medicare Part D, finding that CMS's oversight is limited because data obtained from sponsors does not provide a complete picture of compounded drug ingredients. The audit identified instances where enrollees received FDA-approved drugs potentially misidentified as compounded drugs, drugs subject to misuse (gabapentin) concurrent with opioid prescriptions, and controlled substances (ketamine) not listed on PDE records. OIG made three recommendations to CMS, all of which CMS concurred with.
Philips MRI Elastography Safety Information R2611182
ANSM has recorded a field safety corrective action by Philips affecting MRI systems with magnetic resonance elastography (MRE) installed at healthcare facilities and medical imaging centers. The action is registered under reference R2611182. Affected users have received direct communication from Philips containing the specific safety instructions and required actions. ANSM directs all enquiries regarding this safety action to Philips as the issuing party.
Hologic Mammographe RX 3Dimensions and Selenia Dimensions Safety Notice
ANSM (France) notified healthcare facilities of a safety action conducted by Hologic Inc. for Mammographe RX 3Dimensions and Selenia Dimensions mammography systems, registered under reference number R2609345. Affected users received a direct communication from the manufacturer with further details. This action involves medical imaging equipment used in breast cancer screening.
Cardiac Cryoablation Device Recall - Boston Scientific Polarx System Safety Alert R2610453
ANSM has recorded safety alert R2610453 following Boston Scientific's recommendation to stop use and recall of its Polarx and Polarx Fit cardiac cryoablation balloon catheters, PolarSheath steerable sheaths, and SmartFreeze cryoablation system consoles. Affected healthcare establishments have received direct notification from Boston Scientific. Users seeking further information are directed to contact Boston Scientific directly.
December 2025 Disciplinary Actions: Accusations, Citations, and Decisions
The California Board of Vocational Nursing and Psychiatric Technicians published its December 2025 disciplinary actions list, recording 11 accusations filed, 25 citations issued, and 7 decisions/orders entered against vocational nurses (VN) and psychiatric technicians (PT) licensed in California. Actions span licensees identified by name, license type, and license number across accusation filing dates from December 4–18, 2025, citation issuance dates from December 4–29, 2025, and decision/order filing dates from December 8–19, 2025.
January 2026 Accusations, Citations, and Decisions - Vocational Nurses and Psychiatric Technicians
The California Board of Vocational Nursing and Psychiatric Technicians published its January 2026 enforcement listings, including 17 accusations filed, 6 statements of issues filed, 40 citations issued, and 18 decisions/orders filed against licensed vocational nurses (VN) and psychiatric technicians (PT). The listings contain respondent names, license types, and license numbers only — no specific violations, conduct descriptions, or penalties are detailed in the document.
CA BVNPT Files 40+ Disciplinary Actions Against Nurses and Psychiatric Technicians February 2026
The California Board of Vocational Nursing and Psychiatric Technicians (BVNPT) filed over 40 disciplinary actions in February 2026 against licensed nurses and psychiatric technicians. Actions include 12 accusations filed, 30 citations issued, and 6 decisions and orders entered against respondents holding RN, VN, and PT licenses. Affected licensees include Priscilla Cortez (RN), Angela Surace (VN), Kaitlin Mustard (PT), and numerous others across vocational nursing, psychiatric technician, and registered nursing categories.
PTBC Licensing Enforcement Terms and Definitions
The California Physical Therapy Board (PTBC) published a definitions resource explaining terminology used in its enforcement actions against physical therapists and physical therapist assistants. The document clarifies the distinction between Citations and Fines (administrative, non-disciplinary) versus formal Disciplinary Actions (Accusations, Revocations, Suspensions). Citations remain on a licensee's file for five years before purging, while disciplinary actions carry more serious long-term consequences.
California PTBC Probation, Citations, and Discipline Guidelines
The California Physical Therapy Board published informational guidance on its probation and citation enforcement mechanisms. The page outlines how the Board balances public protection with licensee rehabilitation through its disciplinary guidelines. It directs licensees to related programs including the Substance Abuse Rehabilitation Program and Petition for Penalty Reduction process.
Substance Abuse Rehabilitation Program for Impaired Physical Therapists
The California Physical Therapy Board describes its Substance Abuse Rehabilitation Program, a confidential monitoring and rehabilitation program for licensed physical therapists (PTs) and physical therapist assistants (PTAs) whose ability to practice safely has been affected by substance abuse, alcohol, or mental illness. The program is available to California-licensed PTs and PTAs through self-referral or board referral, and provides assessment, treatment referral, rehabilitation planning, random drug testing, and monitoring services. Successful completion requires a minimum of 24 consecutive months of clean random body-fluid tests and records are destroyed upon completion.
31 California Pharmacy Licensees Face Discipline: Revocations, Probations, Surrenders, Denials
The California State Board of Pharmacy issued disciplinary decisions against 31 individual licensees between October 15 and December 19, 2025. Outcomes include outright revocations (8 cases), revocations stayed with probation (13 cases), voluntary surrenders (2 cases), application denials (4 cases), one public reproval, and one dismissed accusation. Probationary periods range from three to five years, with some cases also ending the right to practice.
12 Licensees Revoked, Probation, or Surrendered During Q2 2026
The California Board of Pharmacy issued disciplinary actions against 12 licensees effective April 1, 2026, including both personal licenses (pharmacy technicians and pharmacists) and facility licenses (compounding and retail pharmacies). Actions ranged from immediate revocation with ended practice rights to stayed revocation with three-year probation subject to conditions, as well as voluntary surrenders and public reprovals with terms.
37 CA Pharmacy Licensees Face Disciplinary Actions Q1 2026
The California Board of Pharmacy issued disciplinary decisions against 37 licensees during Q1 2026 (January 1 – March 31, 2026). Decision effective dates span January 7, 2026 through March 25, 2026. Outcomes include immediate revocations, probations with stayed revocations, public reprovals, and voluntary surrenders, with probation terms ranging from one to five years.
Colorado Adopts Controls on Five Toxic Air Pollutants from Key Industries
The Colorado Air Quality Control Commission adopted emission control measures for five priority air toxic contaminants — benzene, ethylene oxide, formaldehyde, hexavalent chromium compounds, and hydrogen sulfide — under the Public Protections From Toxic Air Contaminants Act (HB22-1244). Affected facilities must reduce emissions through new technologies, adjusted work practices, and less toxic materials. New sources face more stringent requirements than existing sources, and the regulations prioritize reductions near disproportionately impacted communities.
ESCAIDE 2026 Abstract Submissions Open Until 18 May
ECDC has announced the opening of abstract submissions for ESCAIDE 2026, Europe's leading public health conference dedicated to infectious disease epidemiology and public health microbiology. Researchers and public health professionals may submit abstracts via the online platform by 18 May 2026 (23:59 CEST). Notifications of acceptance or rejection will be issued by 30 June, with the conference scheduled for 18–20 November in Stockholm and online.
Three EU/EEA Countries Achieve 90% HPV Vaccination Coverage Target
The ECDC published a report on HPV vaccination programmes in the EU/EEA marking 15 years of progress. Three EU/EEA countries (Iceland, Portugal, Norway) have reached the 2024 EU Council Recommendation target of 90% HPV vaccination coverage among girls by age 15. All EU/EEA countries now recommend HPV vaccination for adolescent girls and boys. A Swedish study showed vaccination before age 17 reduces cervical cancer incidence by 88%. ECDC also launched a new vaccination coverage dashboard.
European Immunization Week 2026: For Every Generation, Vaccines Work
ECDC published a news article marking European Immunization Week 2026 (19–25 April) under the theme 'For every generation, vaccines work.' The article highlights surveillance data including 350 measles cases as of 28 February 2026, nearly 210,000 pertussis cases in 2024 (an eight-fold increase from 2023), and over 25,000 invasive pneumococcal disease cases annually in 2023–2024. ECDC also released a new HPV vaccination programme report and launched a vaccination coverage dashboard for EU/EEA.
Mykronor Noradrenaline 5 μg/mL Medication Error DHPC
HPRA Ireland published a Direct Healthcare Professional Communication (DHPC) from Laboratoire Aguettant regarding Mykronor (Noradrenaline) 5 μg/mL solution for injection/infusion. The DHPC addresses a potential risk of medication errors associated with this product. Healthcare professionals who prescribe, dispense, or administer this noradrenaline formulation should review the communication for specific risk mitigation guidance.
Omnipaque Visipaque 100ml Batch Recall Particles
HPRA Ireland has issued a user-level batch recall for specific lots of Omnipaque 350 mg I/ml Solution for Injection and Visipaque 320 mg I/ml Solution for Injection due to potential particle contamination in 100ml polypropylene bottles. Affected batches are Omnipaque lot 17413362 (expiry 15.10.2028) and Visipaque lot 17230467 (expiry 14.08.2028), both authorised to GE Healthcare AS. Glass bottle presentations are not affected. Pharmacists must quarantine stock, complete the recall form, and notify relevant healthcare facilities.
Drug Safety Newsletter Issue 122: Hydroxycarbamide CGM Interference and Miconazole-Warfarin Interaction
The HPRA Drug Safety Newsletter Issue 122 (April 2026) covers four safety topics for medicines for human use: potential interference of hydroxycarbamide-containing products with continuous glucose monitoring systems; a drug-drug interaction between topical miconazole and warfarin; the importance of reporting suspected adverse reactions to pharmacovigilance; and updates from EMA's PRAC. The newsletter also references Direct Healthcare Professional Communications published on the HPRA website since the prior issue.
ANVISA Discusses Normative Instruction for GLP-1 Pen Manipulation
ANVISA's Collegiate Board will discuss at its April 29 public meeting a proposed normative instruction establishing technical requirements for compounded GLP-1/GIP receptor agonist medications. The instruction covers import procedures, supplier qualification, quality control testing, stability, storage, and transport of active pharmaceutical ingredients for magistral manipulation. The draft is available for public consultation as part of a broader action plan announced April 6, 2026, addressing irregularities in weight-loss pen importation and manipulation.
Anvisa Creates Cosmetovigilance Technical Chamber, Portaria 471/2026
ANVISA has established a Technical Chamber of Cosmetovigilance (CTEC) under Portaria 471/2026, linked to the General Management for Monitoring Products Subject to Health Surveillance (GGMON). The chamber has a consultative nature and comprises five titular members and five alternates from higher education and research institutions across different regions of Brazil, plus representation from the Ministry of Health. The CTEC will analyze and evaluate safety signals, propose regulatory measures, develop methodologies and technical criteria, and qualify data from notification systems and other sources.
Final Results Published, Brazilian Pharmacopeia Selection, 2026-2031 Committees
ANVISA published the final results of the 2026 selection process for the Brazilian Pharmacopeia (Farmacopeia Brasileira), including appeal evaluation outcomes, overall scores, and results by committee. Selected candidates will compose the Technical Thematic Committees that will operate from 2026 to 2031. The Brazilian Pharmacopeia establishes minimum quality, authenticity, and purity requirements for pharmaceutical inputs, medicines, and other health-surveillance products.
CDSCO-IndiaAI Health Innovation Acceleration Hackathon
IndiaAI (under MeitY) and CDSCO have launched the Health Innovation Acceleration Hackathon to develop AI and ML solutions for automating regulatory review of drugs, medical devices, and clinical trials. The competition seeks AI tools for data anonymisation (PII/PHI detection), document summarisation, completeness assessment, and comparison/reporting, to be integrated with CDSCO's SUGAM and MD Online portals. Prize pool is ₹85 lakh; application deadline is 30 April 2026.
Draft Guidelines on Similar Biologics - Regulatory Requirements for Marketing Authorization in India, 2025
CDSCO has published draft guidelines for Similar Biologics (biosimilars) regulatory requirements for marketing authorization in India, replacing existing guidelines to align with recent international standards. The document covers quality considerations, manufacturing process, analytical assessment, preclinical and clinical data requirements, pharmacovigilance, and post-market obligations across 15 sections and 5 annexures. Stakeholders have 30 days from publication to submit comments to biological@cdsco.nic.in.
Interim Order Expedites COVID-19 Drug Importation and Sale
Health Canada signed the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 on September 16, 2020. The Order establishes expedited authorization pathways allowing the Minister to consider urgent public health needs when evaluating drugs for COVID-19, including evidence from foreign regulatory approvals. It also enables more agile establishment licensing and permits the Public Health Agency of Canada to pre-position promising drugs before full authorization. The Order was made under subsection 30.1(1) of the Food and Drugs Act and requires an Order in Council to remain in effect beyond 14 days.
Explanatory Note: Interim Order Respecting Prevention and Alleviation of Drug Shortages in Relation to COVID-19
Health Canada has issued an Interim Order (effective October 16, 2020) granting the Minister of Health new powers to address drug shortages caused or exacerbated by COVID-19. The order authorizes the Minister to compel any person selling a drug to provide information about shortages or potential shortages, and to impose or amend terms and conditions on drug sale authorizations. The order ceases to have effect 14 days after being made unless approved by the Governor in Council.
Proposed Amendments to 10 NYCRR Part 59 - Chemical Analyses for Alcoholic Content
The NY Wadsworth Center has proposed amendments to 10 NYCRR Part 59 governing chemical analyses of blood, urine, breath, or saliva for alcoholic content. The proposed revisions are now open for public comment through April 20, 2026. Comments should be submitted to regsqna@health.ny.gov.
Wadsworth Center Steps in for CDC Disease Testing
The Wadsworth Center, New York's public health laboratory, announced it is prepared to assume testing responsibilities for certain diseases following a pause in CDC testing services. The laboratory's announcement references an Albany Times Union article providing additional details on the transition. This notice serves as an informational redirect to external coverage rather than a standalone regulatory document.
Federal Select Agent Program Annual Reports 2017-2024
The Federal Select Agent Program publishes annual reports covering select agent and toxin regulations, incident data, and laboratory oversight. The 2024 Annual Report was released September 10, 2025, alongside a 2024 Inspection Report Processing Annual Summary released August 20, 2025. The publication index also includes inspection summaries from 2015–2023 and peer-reviewed journal articles on biosafety and select agent program compliance.
Five Select Agents Removed From Regulated List Effective January 16, 2025
HHS and USDA published parallel Final Rules on December 17, 2024 removing five select agents from the regulated list effective January 16, 2025. The removed agents include three Brucella species (B. abortus, B. melitensis, B. suis), African horse sickness virus, and Peronosclerospora philippinensis. The rules also update nomenclature for Ebola and SARS-CoV viruses, designate Nipah virus as Tier 1, and increase the conotoxin exclusion threshold from 100 mg to 200 mg.
Annual Inspection, Biosafety Plan, Drills Guidance
CDC Division of Select Agent and Toxins publishes a comprehensive index of guidance documents for select agent and toxin compliance. The guidance covers annual inspections, biosafety/biocontainment plans, drills and exercises, incident response, security planning, training requirements, and suitability assessments for entities handling select agents and toxins.
HCBS Statewide Transition Plan Training for Multiple Service Areas
North Dakota Department of Health (ND DOH) released training materials covering the 2014 CMS HCBS settings rule (CMS 2249F) across six Medicaid waiver programs: HCBS Waiver, Autism Spectrum Disorder Waiver, Children's Hospice Waiver, Medically Fragile Children's Waiver, Technology Dependent Waiver, and Traditional IID/DD HCBS Waiver. The materials detail HCBS settings requirements, person-centered planning obligations, community integration standards, and CMS compliance expectations for provider-owned and controlled residential settings. ND achieved final CMS STP approval in February 2019.
NCI PowerPoint Presentation Not Found
The North Dakota Department of Health and Human Services website displays a 404 error for the NCI Public Meeting PowerPoint Presentation dated January 4, 2023. The linked PowerPoint file is unavailable and cannot be accessed. No regulatory content, compliance obligations, or substantive information is provided by this page.
Opioid Settlement Advisory Committee Meeting, May 11th
The North Dakota Opioid Settlement Advisory Committee will hold a public meeting on May 11, 2026 from 10 a.m. to 12 p.m. CT at the ND State Capitol in Bismarck, with virtual attendance options available. The agenda includes opioid settlement updates from the ND Attorney General's Office, fund updates from the Opioid Addiction Administrator, and presentations from five Opioid Settlement Fund grantees covering syringe services and addiction treatment programs.
Food Protection Tuesday Training, Virtual, Apr-Dec 2026
The Indiana Department of Health is hosting virtual Food Protection Tuesday Training sessions on select Tuesdays from April through December 2026. Each session runs from 2:00pm to 3:00pm Eastern time. Nine dates are scheduled: April 21, May 19, June 16, July 21, August 18, September 15, October 20, November 17, and December 15. The training is delivered via virtual format and open to food service professionals seeking instruction on food protection practices.
NCRCB Completes Mandatory Ten-Year Rule Review Under N.C. Statute 150B-21.3A
The North Carolina Respiratory Care Board (NCRCB) completed its mandatory ten-year review of all existing rules under N.C. General Statute §150B-21.3A on July 11, 2024. The Board reviewed rules in 21 NCAC 61 and made initial determinations classifying each rule as either 'Necessary' or 'Unnecessary.' Approved rules will be available for a 60-day public comment period beginning August 7, 2024.
Public Hearing on New Rule for Reinstatement of Respiratory Care License
The North Carolina Respiratory Care Board announces a public hearing on September 17, 2025, to receive comments on the permanent adoption of proposed Rule 21 NCAC 61.0206, which establishes the process for reinstatement of a respiratory care license. The proposed rule was published in the NC Register, Volume 40, Issue 05. Written comments will be accepted until 5:00 PM on November 4, 2025.
Apple Health Client Support Contact Information
The Washington Health Care Authority has published contact information for Apple Health (Medicaid) clients, behavioral health clients, providers, and Public Employees Benefits Board members. The page organizes program-specific contacts including phone numbers, email addresses, online forms, and business hours by inquiry type.
Drug Delivery System and Methods of Using the Same
The USPTO granted Axogen Corporation Patent US12599701B2 for a drug delivery system combining polydioxanone polymer with neuro-regenerative or immunosuppressive agents to form an implantable biomaterial. The patent includes 16 claims covering the method of combining, melting, and extruding the polymer with at least one immunophilin ligand. The invention is classified under CPC codes including A61P 25/02 (nervous system therapeutic activity) and A61L 27/54.
Biodegradable Lung Sealant PEG Hydrogel Patent Granted to Ethicon
USPTO granted patent US12599624B2 to Ethicon, Inc. for a rapid-setting biodegradable lung sealant comprising two multi-arm polyethylene glycol (PEG) compositions. The first PEG composition contains an alkaline buffer and the second contains a mildly acidic buffer, providing optimized setup time and extended working time. The formulation may include tocopherol as a radioprotectant and a colorant for improved visualization against lung tissue. The patent contains 22 claims and is classified under CPC codes A61K and A61P.
Dr. Gerald Buchoff Consent Order - License Discipline for Veterinary Negligence
The New Jersey Board of Veterinary Medical Examiners issued a Consent Order against Dr. Gerald Buchoff for multiple acts of negligence in treating a ten-year-old Yorkshire Terrier named Oliver in July-August 2020. The Board found violations including premature removal of IV port post-surgery, failure to replace IV when the dog crashed, failure to take pre-surgical x-rays, failure to respond appropriately to a medical emergency, and failure to maintain proper documentation. Dr. Buchoff must pay a $7,500 civil penalty and complete 5 credit hours of Board pre-approved emergency protocol continuing education within six months.
Dr. Gerald Buchoff Consent Order - Veterinary License Discipline
The New Jersey Board of Veterinary Medical Examiners issued a Consent Order against Dr. Gerald Buchoff (License No. 29VI00222600) for multiple acts of negligence in treating a Yorkshire Terrier named Oliver in July-August 2020. The Board found violations of N.J.S.A. 45:1-21(d) including premature removal of IV port post-surgery, failure to take pre-surgical x-rays, failure to respond appropriately to a medical emergency, failure to refer to an emergency veterinarian, and failure to maintain proper documentation. Respondent agreed to pay a civil penalty of $7,500 over 18 months and complete 5 credit hours of Board pre-approved emergency protocol continuing education within 6 months.
Final Consent Order - Chigounis Evans W
The NJ Massage Therapy Board issued a Final Consent Order regarding licensed massage therapist Chigounis Evans W. The document finalizes a disciplinary settlement addressing violations of massage therapy practice standards. The consent order establishes specific requirements and/or restrictions on the licensee's practice in New Jersey.
FY 2025-26 Q2 Quarterly Performance Report Released
The Florida Department of Health's Division of Medical Quality Assurance (MQA) has released the FY 2025-26 Quarterly Performance Report for Quarter Two. The report covers MQA's key trends in licensing, enforcement, and information, along with financial insights. Required under sections 456.005 and 456.025(9), Florida Statutes, the report provides stakeholders with quarterly snapshots of performance statistics, accomplishments, and activities including the HB 975 Cleared to Care campaign, MQA's Virtual Agent ELI, and unlicensed activity outreach.
New Background Screening Requirements for Health Care Practitioners Effective July 1, 2025
The Florida Acupuncture Board announced that effective July 1, 2025, all health care practitioners in Florida must comply with new background screening requirements when applying for initial licenses or renewing existing licenses. The new requirements are integrated into the licensure process, with renewal applications opening 90 days before license expiration. Practitioners who fail to complete the required background screening will be prevented from obtaining or renewing their license.
Dr. Gerald Buchoff Consent Order for Veterinary Negligence
The New Jersey Board of Veterinary Medical Examiners issued a Consent Order against Dr. Gerald Buchoff for multiple acts of negligence in treating a Yorkshire Terrier in July-August 2020, resulting in the dog's death. The Order requires Dr. Buchoff to complete 5 credit hours of emergency protocol continuing education within 6 months and pay a $7,500 civil penalty over 18 months. The Board found violations of N.J.S.A. 45:1-21(d) including premature IV port removal, failure to maintain emergency equipment, and inadequate documentation.
Nicole Desmond DVM Settlement - $2,000 Civil Penalty for Negligence
The New Jersey State Board of Veterinary Medical Examiners issued a settlement letter to Dr. Nicole Desmond requiring a $2,000 civil penalty for repeated acts of negligence, malpractice, or incompetence related to refusal of emergency care and failure to provide follow-up care to a patient. The settlement must be accepted within 21 days or the matter proceeds to formal disciplinary proceedings.
Dr. Katelyn Felts Veterinary Settlement Letter
NJ State Board of Veterinary Medical Examiners completed review of complaint #VFT-2025-05817 concerning Dr. Katelyn Felts' treatment of a dog and patient record deficiencies. Board found violation of patient record regulation N.J.A.C. 13:44-4.9 and offers settlement requiring $500 civil penalty within 21 days to avoid formal disciplinary proceedings.
Oregon Board Massage Therapy Rules Committee Meeting March 16
The Oregon Board of Massage Therapists Rules Committee will meet on March 16, 2026, from 3:30 PM to 5:30 PM virtually via GoToMeeting. The agenda includes discussion of SB3819 (incorporating felony, placard requirements, and civil penalties), facility permit renewability, CPR/BLS requirements, mandatory reporter training for continuing education, zombie licenses, and ethics rules regarding dual relationships.
NCBMBT Winter 2022 Newsletter
The NC Massage Therapy Board published its Winter 2022 newsletter reminding Licensed Massage and Bodywork Therapists of license renewal procedures, continuing education requirements (24 hours including 3 ethics hours), complaint filing processes, and best practices for client communication and documentation. The newsletter notes that online CE completion is permitted for the 2023 renewal period only, and that establishment and individual licenses must be displayed at practice locations.
2024 Winter Board Newsletter: CE Requirements, License Renewals, and Disciplinary Actions
The NC Board of Massage and Bodywork Therapy issued its 2024 Winter Newsletter reminding licensees of 2024 continuing education requirements (24 hours including 3 ethics hours, 12 in-classroom minimum), license renewal procedures with December 31 deadline, and new late fee provisions. The Board announced new members Laura Ford and Nancy Harrell appointed to positions previously held by Rachael Crawford and Valory Hicks, with officer elections including Amy Swink as Chair and Robert Reeves as Vice Chair. The newsletter also outlines establishment licensure requirements, mandatory reporting obligations, and license display requirements for LMBTs and establishment owners.
Maldonado Yehudi Athletic Trainer Consent Order
The New Jersey Athletic Trainer Board issued a consent order resolving disciplinary proceedings against Maldonado Yehudi, an athletic trainer licensed in New Jersey. The consent order addresses violations of the Athletic Trainer Licensing Act and establishes terms for resolution of the matter. Athletic trainers and healthcare employers in New Jersey should review the consent order terms for compliance implications.
Abruzzo Reprimanded for NJ Unlicensed Accountancy, $5,000 Fine
The New Jersey State Board of Accountancy issued a Consent Order on April 11, 2012 against Christopher Abruzzo for engaging in the unlicensed practice of public accountancy from approximately January 2004 through June 2009. The Board reprimanded Abruzzo and assessed a civil penalty of $5,000, payable within 30 days per N.J.S.A. 45:2B-62(a). The respondent held a valid New York CPA license but never obtained a New Jersey license.
Wyoming Board Offers ACCME CME Tracking Service for Physicians
The Wyoming Board of Medicine is offering physicians free access to ACCME's CME tracking service via the Program and Activity Reporting System (PARS). The service automatically reports accredited CME credits to participating state boards, simplifying compliance verification for the Board's biennial CME audits.
Wyoming Board of Medicine Regular Meeting, April 16-17, 2026
The Wyoming Board of Medicine published its regular meeting agenda for April 16-17, 2026, to be held at the Board office in Cheyenne and via video conference. The two-day agenda covers license application reviews, disciplinary proceedings including four consent decrees, IMLC policy discussions, operational reports, and officer elections. Four disciplinary dockets are scheduled for executive and public sessions.
License Investigation Scam Alert for Wyoming Physicians
The Wyoming Board of Medicine issued an alert warning Wyoming physicians and physician assistants about scam calls from an individual claiming to be a Board investigator. The caller, who uses the name 'Brian Clark' and spoofs the Board's phone number, threatens license action and media exposure for alleged illegal conduct. The Board states it has no one by that name and does not conduct investigations in this manner. The alert advises recipients to verify suspicious calls by calling the Board office directly at 307-778-7053.
Interim Consent Order Temporarily Suspends Professional Counselor
The NJ Counseling Board Professional Counselors Examiner Committee issued an Interim Consent Order on January 14, 2026, temporarily suspending the license of a professional counselor. This enforcement action restricts the individual's ability to practice counseling in New Jersey pending further review.
Dana McLaughlin LPC Restrictions Terminated, New Jersey
The New Jersey Professional Counselor Examiners Committee has issued an order terminating all license restrictions imposed on Dana McLaughlin, LPC (License No. 37PC00581700). The restrictions, originally imposed in December 2022 following a complaint, included a stayed suspension, supervised practice requirements, and a prohibition on supervising others. The Committee determined that McLaughlin satisfied all conditions of the Consent Order, including completing required coursework and receiving supervisor attestation of readiness for independent practice. McLaughlin may now practice professional counseling in New Jersey without restriction.
Tara M. King Summary Order of Suspension
The New Jersey Professional Counselor Examiners Committee issued a Summary Order of Suspension against Tara M. King (License No. 37PC00161400) for failure to cooperate with a Board investigation. The licensee failed to respond to two letters of inquiry sent via email, regular mail, and certified mail, constituting professional misconduct under N.J.A.C. 13:45C-1.2 and 1.3 and N.J.S.A. 45:1-21(e). The license to practice professional counseling in New Jersey is hereby suspended until further Order of the Board.
Internationally Trained Dentists Becoming Licensed Dental Hygienists
Virginia's HB 1036 and SB 282 permit the Board of Dentistry to license dental hygienists who were eligible to practice dentistry outside the United States, effective July 1, 2026. The Board must promulgate implementing regulations outlining criteria for foreign-education assessments, supervision levels, and clinical exam requirements. The laws authorize expedited procedures bypassing standard APA rulemaking steps; however, no projected timeline for finalizing regulations has been established.
Two New Directors Join Virginia Board of Dentistry
The Virginia Board of Dentistry August 2025 newsletter announces two new directors joining the Board and provides updates on Continuing Education (CE) audits, showing 81% of dentists and 72% of dental hygienists currently in compliance. The Board also reports 50% completion of OMS audits and discusses progress toward the Dental and Dental Hygiene Compact, with projected implementation in late 2026 to early 2027.
New Board Member Dr. Quigg Joins Virginia Dentistry Board
The Virginia Board of Dentistry announced Dr. Richard Quigg as a new board member. The February 2026 Briefs reports 2024 CE audit results showing 78% compliance among 77 dentists and 60 hygienists audited, with 16% non-compliant facing public discipline. An audit of 24 Oral and Maxillofacial Surgeons with cosmetic procedure certificates found 3 fully compliant; 12 received Advisory Letters and 9 received CCAs for profile update failures. The Board recognized CE Broker as its official voluntary CE tracking system.
Christina Blanchard Physical Therapy License Suspension
The NJ Physical Therapy Board issued a license suspension order for physical therapist Christina Blanchard (License #40QA00670000) effective September 10, 2025. The enforcement action modifies her legal authority to practice physical therapy in New Jersey. Affected parties include the licensee, current patients receiving treatment, and referring healthcare providers who must seek alternative care arrangements.
Fernando Salazar Interim Consent Order - License Surrender
The New Jersey Board of Physical Therapy Examiners issued an Interim Consent Order requiring Fernando Salazar to voluntarily surrender his license to practice physical therapy following his arrest in California on sexual battery charges. The surrender is deemed a temporary suspension effective immediately. Respondent must cease and desist from practice, surrender all credentials, and may only apply for reinstatement after all criminal charges are fully resolved.
NJ Physical Therapy Board Interim Suspension Order - Possible Criminal Activity
The NJ Physical Therapy Board issued an interim suspension order against a licensee based on evidence of possible criminal activity. The order references a third-degree crime and cites information that, if proven, would constitute criminal conduct. This interim suspension is effective immediately and remains in place pending further board action or resolution of the underlying criminal matter.
Montana Dental Board Archived Rule Notices
The Montana Board of Dentistry maintains an archive of historical dental practice rule notices on its regulatory website. This index page provides access to past dental regulations and board decisions. No new regulatory obligations are created by this archived listing.
Montana Board of Dentistry Members Listed by Role
The Montana Board of Dentistry published its current board membership listing, identifying ten members including the Board Chair, Denturists, Dentists, Hygienists, and Public Members. Board members are appointed by the Governor and confirmed by the Senate. The listing provides a general contact email for board inquiries.
Montana State Board of Dentistry Meetings
The Montana Department of Labor & Industry published the Board of Dentistry meeting schedule listing upcoming committee and full board meetings through March 2027, along with past meeting minutes and recordings. No regulatory actions, compliance obligations, or enforcement matters are presented. The Board holds hybrid meetings at 301 S Park Ave in Helena, MT, with some meetings virtual-only or partially closed to the public.
Christopher Abruzzo Unlicensed Accountancy Consent Order
The New Jersey State Board of Accountancy issued a Consent Order against Christopher Abruzzo for engaging in the unlicensed practice of public accountancy in New Jersey from January 2004 through June 2009. The Board found the respondent violated N.J.S.A. 45:2B-62(a) and imposed a reprimand along with a civil penalty of $5,000, payable within 30 days of the order. Failure to remit payment will result in filing a Certificate of Debt.
Oregon Board of Dentistry Amends Nine Rules, Updates Fees
The Oregon Board of Dentistry filed amendments to nine administrative rules (OBD 2-2025), effective December 1, 2025. The filing includes updated biennial license fees for dental, dental hygiene, and dental therapy professions, along with new patient care standards requiring written informed consent for botulinum toxin and dermal filler administration. Additional changes address medication storage requirements and expand dental hygienist scope of practice to include extraoral procedures.
Berkowitz PhD Settlement - Professional Misconduct Inquiry
The New Jersey State Board of Psychological Examiners issued a modified offer of settlement to Dr. David L. Berkowitz following a consumer complaint finding probable cause for professional misconduct. The Board determined Dr. Berkowitz made an inappropriate statement to a prospective client who missed appointments, stating 'You must have dementia,' in violation of N.J.S.A. 45:1:21(e). The settlement requires a $250 civil penalty and a cease-and-desist commitment. The respondent has 15 days to accept the settlement terms or the matter will be referred for formal enforcement proceedings.
Gary Borer - Modified Offer Settlement
The New Jersey Board of Psychological Examiners filed a Modified Offer Settlement with Gary Borer on January 23, 2026. The settlement represents a disciplinary resolution concerning the licensed psychologist's professional practice. The specific terms, conditions, and any resulting restrictions on the licensee's practice are contained within the filed settlement document.
Modified Settlement Offer - Lee, Case No. 8B.S., February 10, 2026
The New Jersey Board of Psychological Examiners filed a Modified Settlement Offer for Case No. 8B.S. on February 10, 2026. This document modifies a prior settlement offer related to professional licensing discipline for an individual named Lee. The settlement modifies the terms of a previous settlement offer as filed with the Board.